Elysium’s mission is to reduce suffering from severe acute pain, opioid-use disorder (OUD), and fatal opioid overdose by developing first- or best-in-class products with profiles that address the key limitations and dangers associated with opioids used today. Our pipeline consists of 3 diverse platforms with broad applicability across several areas of significant unmet need:
Technologies
1. O2P™ (Oral Overdose Protection) – Lead platform Traditional opioids are easy to abuse, with euphoria and risk of respiratory depression increasing with every pill consumed. O2P provides self-limiting exposure to active opioid and prevents overdose.
2. XpiRx™ (Forced Expiration) 70-year half-life of traditional opioids creates a surplus supply of readily available pills that can end up on the streets. XpiRx opioids, whose potency expires after the prescribed-use period, reduce abuse and prevent fatal overdoses.
3. SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) Existing rescue agents are too short-acting and weak against synthetic opioids, often requiring multiple doses. SOOPR lasts up to 24 hours and is more effective against synthetic opioids (e.g., fentanyl, nitazenes) than today’s standard-of-care
Elysium has a highly attractive risk/reward profile:
1. High-probability of Success: In vitro and in vivo proof-of-concept data for its new chemical entities that are comprised of FDA-approved drugs
2. Capital Efficiency: Leveraging non-dilutive grant funding, ~$16M to-date
3. Platform Opportunity: Diversified portfolio of programs addressing the key underlying factors that are driving the opioid crisis and could yield multiple products within 3-5 years
4. Market: Multi-billion-dollar market potential, with weak direct pipeline competition
5. Intellectual Property: Strong protection, with issued patents in the US and internationally, including composition of matter
Company Details
- Employees
- 6
- Founded
- -
- Address
- 1201 E Market St.,
- Phone
- (925) 399-7246
- Industry
- Biotechnology
- Website
- http://www.elysiumrx.com
- Keywords
- pain therapy, drug research, drug development, oral overdose, opioid epidemic, opioid crisis, opioid abuse, abuse-deterrence, diversion, chemistry, addiction.
- HQ
- Akron, OH
Elysium Therapeutics, Inc. Questions
Elysium Therapeutics, Inc.'s helpline number is (925) 399-7246
Elysium Therapeutics, Inc.'s website is http://www.elysiumrx.com
Elysium Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/elysium-therapeutics-inc-
Elysium Therapeutics, Inc. has
6 employees.
View email and phone details for 6
employees at Elysium Therapeutics, Inc..
Elysium Therapeutics, Inc.'s industry is
Biotechnology
Elysium Therapeutics, Inc.'s top competitors are
Nuvox Therapeutics,
Rheumagen,
Photonpharma,
Biodesix, Inc.,
Umoja Biopharma,
Trampoline Pharma, Inc.,
Ambrosia Biosciences Inc.,
Enveda,
Gelsana,
Darwin Biosciences.
Elysium Therapeutics, Inc.'s categories are Biotechnology
Elysium Therapeutics, Inc.'s founding year is 2013
